Traws Pharma (TRAW) Company Report

Traws Pharma, Inc. completed enrollment in its 90-patient, open-label Phase 2 study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, for mild-to-moderate COVID-19 in both PAXLOVID®-eligible and ineligible patients.
Ongoing clinical results for ratutrelvir indicate a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date, and faster time to sustained symptom resolution.
The company announced plans for an added indication for tivoxavir marboxil as a prophylactic treatment for seasonal influenza.
A new compressed tablet formulation of tivoxavir marboxil is predicted to provide 28-day protection from influenza, with a human influenza prophylaxis challenge study time slot secured for June 2026.

Jan 26, 2026, 1:30 PM

Traws Pharma Files IND for Influenza Therapy and Updates Ratutrelvir COVID-19 Study Results

TRAW

New Projects/Investments

Traws Pharma, Inc. (TRAW) filed a U.S. Investigational New Drug (IND) application with the FDA for tivoxavir marboxil (TXM), a potential influenza therapy, which is an important step towards its formal consideration for inclusion in the strategic national stockpile.
The company announced updated interim results from its ongoing Phase 2 clinical study of ratutrelvir for mild-to-moderate COVID-19, confirming a differentiated clinical profile compared to PAXLOVID®.
Ratutrelvir-treated patients demonstrated a faster time to sustained symptom alleviation and resolution (12 days) compared to 14 days for PAXLOVID®-treated patients (p<0.014).
The study also reported no COVID-19 symptom or virologic rebound events in ratutrelvir-treated patients, and fewer adverse events, with the drug being well tolerated in PAXLOVID®-ineligible patients.
Full enrollment for the ratutrelvir study is expected in January 2026.

Jan 13, 2026, 12:00 PM

Traws Pharma Reports Positive Interim Clinical Data for Ratutrelvir

TRAW

New Projects/Investments

Traws Pharma announced positive interim clinical data from an ongoing Phase 2 study for ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19.
The interim analysis, published on December 17, 2025, indicated that ratutrelvir demonstrated a differentiated clinical profile compared to PAXLOVID™, with fewer adverse events and no viral rebounds observed to date.
The study showed activity in PAXLOVID-ineligible patients, with six patients (24% of the ratutrelvir cohort) in this group demonstrating symptom improvement consistent with the broader ratutrelvir-treated cohort.
The most commonly reported adverse event for ratutrelvir was mild dyspepsia in 2 patients (7.6%), with no dysgeusia or ritonavir-associated adverse effects, while 4 patients (30%) in the PAXLOVID™ comparator arm reported common adverse events.
Final data analysis from the study is anticipated in January 2026.

Dec 17, 2025, 11:00 AM

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

TRAW

Earnings

Management Change

New Projects/Investments

Traws Pharma reported a net loss of $4.0 million, or $0.34 per share, for the third quarter ended September 30, 2025, compared to a net loss of $8.5 million, or $1.49 per share, for the comparable period in 2024, with zero revenue in Q3 2025. The company's cash and cash equivalents were $6.4 million as of September 30, 2025, down from $21.3 million as of December 31, 2024, with cash projected to support planned operations into Q1 2026.
The company expects topline data by year-end 2025 from its Phase 2 non-inferiority study of ratutrelvir (for COVID) and a separate single-arm study in PAXLOVID®-ineligible subjects.
Traws Pharma is advancing discussions with BARDA for the inclusion of Tivoxavir Marboxil (TXM) in the drug stockpiling initiative for pandemic preparedness. Additionally, the Board confirmed the permanent appointments of Iain Dukes as CEO and Charles Parker as CFO on October 6, 2025, and named John Leaman as an Independent Board Director.

Nov 13, 2025, 12:01 PM

Traws Pharma Acquires Antiviral Compound Assets

TRAW

M&A

New Projects/Investments

Traws Pharma, Inc. acquired certain assets from Viriom, Inc. for $2,350,000 in cash on September 9, 2025.
The acquired assets include intellectual property and other related assets for a pyrrolidine antiviral compound and its program pipeline.
The transaction was identified as a related party transaction, as Traws Pharma's Chief Operating Officer and Chief Medical Officer hold positions and interests in Viriom.
Traws Pharma's Audit Committee and Board of Directors reviewed and approved the agreement, determining it was in the company's best interest and the purchase price was fair and reasonable.